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ABSTRACT
Cyclosporin A (CsA) is a widely employed immunosuppressive drug that is associated with several side 
effects, among then hepatotoxicity. Heteropterys tomentosa is a Brazilian plant efficient in reducing damage 
caused by CsA on the rat testis and prostate. The aim of this study was to evaluate the effect of CsA and 
H. tomentosa (administered isolated or simultaneously) on the liver of Wistar rats. The animals were treated daily 
with water (control), CsA (15mg/kg/day), H. tomentosa infusion or CsA+H. tomentosa, for 21 or 56 days. The 
treatments did not alter liver morphology or cause fibrosis. H. tomentosa administered for 21 days increased the 
number of hepatocyte nuclei and Kupffer cell volumetric proportion. After 56 days of treatment, H. tomentosa 
administration did not alter the parameters analyzed. Biochemical plasma dosages and liver stereology showed 
impairment caused by CsA-treatment after 21 days; these results were not observed after 56 days of treatment. 
The simultaneous treatment with CsA and H. tomentosa for 21 or 56 days did not alleviate nor accentuate CsA 
hepatic effects. The present study showed that the 21 days treatment with CsA caused more alteration to the liver 
than the 56 days treatment; this could be related to hepatic recovery after the long term treatment.
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INTRODUCTION
Cyclosporin A (CsA) is a neutral, hydrophobic, 
cyclic peptide with 11 amino acids (Shevach 1985) 
that is administered as an immunosuppressant drug 
(Shevach 1985, Matsuda and Koyasu 2000). This 
drug is widely used to treat autoimmune diseases, 
being associated with reduction in the number of 
hospitalization days for transplanted patients and 
for rejection episodes (Rezzani 2004). However, 
several side effects are associated with CsA 
treatment such as: nephrotoxicity (Bertani et al. 
1987, Baliga et al. 1997, Fellstrom 2004, Rezzani 
2004, Hagar et al. 2006, Josephine et al. 2006, 
2007, Rezzani et al. 2006b), hepatotoxicity (Durak 
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et al. 2004, Hagar 2004, Rezzani 2004, 2006, 
Kurus et al. 2008, Bohmer et al. 2011), testicular 
dysfunction (Monteiro et al. 2008) and damages to 
the ventral prostate (Freitas et al. 2012a). Most of 
these are related to the increase of reactive oxygen 
species (Wolf et al. 1997, Buffoli et al. 2005, 
Rezzani 2006), causing damage to tissue structure 
and functional disorders (Whiting et al. 1983).
Several researchers have investigated subs-
tances that reduce CsA side effects (Rezzani et al. 
2001, 2006a, b, Parra Cid et al. 2003, Monteiro et 
al. 2008, Wongmekiat et al. 2008). Heteropterys 
tomentosa A. Juss. (sin. Heteropterys aphrodisiaca 
O. Mach.), a native species from the Brazilian 
“Cerrado” (a savannah-like biome), is used by 
the local population as a hypoglycemiant to treat 
diabetes (Guarim Neto and Morais 2003, Macedo 
and Ferreira 2004), as an aphrodisiac and to treat 
nervous weakness and collapse (Corrêa 1984, 
Pott and Pott 1994). The antioxidant properties 
of H. tomentosa root extract (BST0298) were 
demonstrated by Mattei et al. (2001), and this same 
extract was also efficient in the recovery of learning 
and memory of aged rats (Galvão et al. 2002). H. 
tomentosa root infusion has been successfully 
used to reduce CsA-related effects on testicular 
tissue (Monteiro et al. 2008), ventral prostate and 
biochemical parameters related to hepatotoxicity – 
plasma levels of glutamic oxaloacetic transaminase, 
total and indirect bilirubin and cholesterol (Freitas 
et al. 2013).
Considering the well documented hepatic 
damage caused by CsA, which is probably due to 
oxidative stress, and the potential of H. tomentosa 
as an antioxidant, we investigated the potential 
benefits of using this medicinal plant against the 
CsA-related hepatotoxicity. The following aspects 
were studied: (1) determination of the side effects 
of CsA on the liver structure and function; (2) 
evaluation of hepatotoxicity caused by H. tomentosa 
intake; (3) effects of simultaneous treatment with 
CsA and H. tomentosa.
MATERIALS AND METHODS
PREPARATION OF THE TREATMENT SOLUTIONS
The methodology used for infusion preparation 
was the same as that used by previous authors 
(Monteiro et al. 2008, 2011, Gomes et al. 2011, 
Freitas et al. 2012b, 2013). In brief, Heteropterys 
tomentosa A. Juss. (sin. Heteropterys aphrodisiaca 
O. Mach., herbarium CPAP number 21625) roots 
were obtained from plants cultivated by Embrapa 
Pantanal in Corumbá, MS, Brazil. The plants were 
grown in controlled conditions of soil, fertilization 
and irrigation, without insecticides. The roots 
were harvested, dried and ground. The infusion 
was prepared immersing ground roots (75.76mg/
kg of body weight) in 100mL of boiled water; the 
animals’ weight was used to calculate quantity 
of ground roots. The infusion was maintained at 
room temperature for 4 hours, and then filtered. It 
was kept at 4° C and used for two days.
Cyclosporin A (Sandimmun Neoral®, Novartis 
Pharma AG, Switzerland) was administered in 
a therapeutic dose (15mg/kg body weight) as in 
previous studies (Chung et al. 2005, Kotolová et 
al. 2006, Monteiro et al. 2008, Bohmer et al. 2011, 
Freitas et al. 2012a, 2013).
EXPERIMENTAL ANIMALS AND PROTOCOL
This experimental protocol was carried out 
according to the standards of the Brazilian Society 
for Laboratory Animals Sciences (SBCAL/COBEA) 
and was approved by the Ethics Committee for 
Animal Studies of the State University of Campinas 
(Protocol number 2295-1). The treatment protocol 
was similar to that previously employed (Monteiro 
et al. 2008, Freitas et al. 2013).
Forty Wistar rats (Rattus norvegicus albinus), 
eight weeks old, were obtained from the Multi-
research Center for Biological Investigation of 
Laboratory Animal - CEMIB (State University of 
Campinas, Campinas - SP, Brazil) and maintained 
under standard conditions with 12h light/dark 
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periods, fed with commercial chow and water “ad 
libitum”. They were separated into two groups 
of 20 animals each. One group was treated for 
21 days and the other for 56 days. In each group, 
the animals were separated in 4 subgroups (n=5 
in each): Control groups (CG) received 0.5mL of 
distilled water; CsA-treated groups (CsA) received 
CsA diluted in 0.5 mL distilled water; H. tomentosa 
treated groups (Ht) received 0.5mL of infusion; 
and groups treated with CsA and H. tomentosa 
(CsA+Ht) received the CsA dose diluted in 0.5 mL 
of infusion. All treatments were administered daily, 
by gavage.
The administrations of CsA for 21 (Buffoli et 
al. 2005, Rezzani et al. 2005a, b, Türk et al. 2007) or 
56 days (Monteiro et al. 2008, Freitas et al. 2012a, 
2013) were chosen based on previous experiments 
reported in literature.
COLLECTION OF THE BIOLOGICAL SAMPLES
The animals were weighed and anesthetized 
with Xylazine and Ketamine (5 and 80 mg/kg, 
respectively) by intramuscular injection. Blood was 
collected from the left ventricle by cardiac puncture 
using Vacuette® tubes with heparin, centrifuged at 
3500rpm for 10 minutes (4° C) and the plasma was 
collected for further biochemical analyses. The 
liver was collected and weighed. Liver relative 
weight (%) was calculated using the formula: 
(Liver weight x 100)/ body weight.
PLASMA BIOCHEMISTRY
The plasma was used to quantify the levels of 
glucose (Kit Laborlab®, enzymatic and colorimetric 
methods), triglycerides (Kit Bioclin®, enzymatic 
and colorimetric methods), total cholesterol (Kit 
Laborlab®, enzymatic and colorimetric methods), 
total proteins (by refractometry, analysis made 
at VetPat Laboratory), creatinine (Kit Bioclin® 
Kit, colorimetric and kinetic methods), alkaline 
phosphatase (Kit Laborlab®, kinetic method), 
glutamic pyruvate transaminase/aspartate amino-
transferase (GPT/AST) (Kit Bioclin®, colorimetric 
method) and glutamic oxaloacetic transaminase/
alanine aminotransferase (GOT/ALT) (Kit Bioclin®, 
colorimetric method).
LIGHT MICROSCOPY
Liver fragments were fixed in 4% paraformaldehyde 
(in phosphate buffer 0.1M, pH 7.4) for 24 hours, at 
room temperature. The fragments were washed in 
the same buffer, dehydrated in ethanol, cleared in 
xylol and embedded in paraffin (Histosec®, Leica). 
The tissue was sectioned with 5µm thickness. One 
slide was stained with hematoxylin and eosin for 
morphological, morphometrical and stereological 
analyses. Another slide was stained with Masson’s 
trichrome (EasyPath® kit) for fibrosis detection.
MORPHOMETRICAL AND STEREOLOGICAL ANALYSES
The proportions of hepatocytes (nuclei and 
cytoplasm), sinusoid capillaries and Kupffer cells 
were estimated using a grid with 130 intersections 
over digital images (40x objective). Ten images 
were analyzed per animal. The number and 
diameter of all hepatocyte nuclei were counted and 
measured, respectively, in 10 fields per animal (40x 
objective), in which each field had 2.97x104 µm2. 
The number of hepatocyte nuclei (HN) per µm2 
was calculated (HN/ µm2 = Number of Hepatocytes 
per field / field area). Hepatocyte nuclei volume 
(NV) was calculated using the formulas: area=πr2 
and volume= 4/3πr3. The hepatocyte cytoplasm 
volume (CV) was calculated using the formula: CV 
= (NV x cytoplasm proportion)/nuclei proportion. 
The hepatocyte volume was the sum of nuclei and 
cytoplasm volumes.
STATISTICAL ANALYSES
A nonparametric test (Kruskal Wallis Multiple 
Comparison) was performed using the software 
Minitab 16. For all the tests the significance was 
95%. All values are shown as mean ± standard 
deviation (SD).
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RESULTS
CYCLOSPORIN A - EFFECTS ON LIVER
CsA treatment did not alter the liver absolute and 
relative weight (Figure 1). The tissue structure did 
not show any alteration either (Figures 2 and 3) 
and fibrosis was not observed even after 56 days 
of treatment.
Volumetric proportions of hepatocytes were 
reduced in the group treated with CsA for 21 
days (p=0.045); and the volumetric proportions 
of sinusoids increased 29.06%, however this 
alteration was not statistically significant. These 
results were not observed after treatment with 
CsA for 56 days (Table I).
The treatment with CsA for 21 days increased 
total cholesterol (p=0.021) and in comparison to the 
control group (Table II). GOT levels were 40.38% 
higher in the CsA group when compared to the 
control, however the difference was not statistically 
significant (p=0.06). Yet, the treatment with CsA for 
56 days increased GPT levels (p=0.012) (Table II).
Heteropterys tomentosa - EFFECTS ON THE LIVER
The treatment with H. tomentosa (during 21 and 
56 days) did not alter liver absolute and relative 
weights (Figure 1) or the morphology (Figures 2 
and 3) and nor did it cause fibrosis. However, an 
increase of the volumetric proportion of Kupffer 
cells was observed after treatment with the 
infusion for 21 days (p=0.013). Furthermore, these 
animals showed an increase of hepatocyte nucleus 
proportion and a reduction of their cytoplasm 
(p=0.003) (Table I). Higher number of hepatocyte 
nuclei was found per µm2 (p=0.023). The treatment 
with H. tomentosa also reduced the total and the 
cytoplasmic volume of hepatocytes (p=0.002 and 
0.001 respectively) (Table I).
No alterations of hepatic morphometry/
stereology and plasma parameters were observed 
after the treatment with H. tomentosa for 56 days 
(Tables I and II).
CSA AND H. tomentosa ASSOCIATED - EFFECTS ON THE LIVER
As observed in the other groups, simultaneous treat-
ment with CsA and infusion did not alter liver absolute 
and relative weights (Figure 1) or morphology 
(Figures 2 and 3) and did not cause fibrosis.
The group CsA+Ht (21 days) did not show 
the alterations observed for the CsA group 
(21 days) (Table I). On the other hand, in this 
group the volumetric proportion of Kupffer cells 
increased (p=0.002). This was also observed for 
animals treated only with H. tomentosa (during 
Figure 1 - Liver absolute (g) and relative weight (%). Control, treated with CsA (CsA), Heteropterys tomentosa (Ht) and 
CsA + H. tomentosa (CsA+Ht), for 21 or 56 days.
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Figure 2 - Liver (H&E staining). Control (A), treated with CsA (B), H. tomentosa infusion (C) 
and both substances (D), for 21 days. Hep: hepatocytes; white arrows: Kupffer cells; black arrows: 
sinusoids. Bars= 50µm.
Figure 3 - Liver (H&E staining). Control (A), treated with CsA (B), H. tomentosa infusion (C) and both 
(D) for 56 days. Hep: hepatocytes; white arrows: Kupffer cells; black arrows: sinusoids. Bars= 50µm.
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21 days). Higher hepatocyte nuclear volume 
was observed when compared to the control and 
the CsA group (21 days) (p=0.004) (Table I). 
As observed for the Ht group, the simultaneous 
treatment with CsA and H. tomentosa also caused 
reduction of hepatocyte volume (p=0.012), due 
to the reduction on cytoplasm volume (p=0.012) 
(Table I).
In the CsA+Ht group (21 days) the levels of 
GOT did not differ significantly in relation to the 
control or the CsA group (Table II). The plasma 
creatinine levels were higher in CsA+Ht group 
(21 days) when compared to the control (p=0.049) 
and CsA (p=0.02) (21 days) (Table II).
Despite the results observed after 21 days of 
treatment, animals treated with both infusion and 
CsA for 56 days showed an increase in the number 
of hepatocyte nuclei per µm2 (p=0.04) (Table I). 
Total cholesterol and GPT levels were increased 
in CsA+Ht group (56 days) when compared to the 
control (p=0.044 and 0.001, respectively) (Table II).
DISCUSSION
Hepatotoxicity induced by CsA administration is 
widely reported in literature (Wolf et al. 1997, Durak 
et al. 2004, Hagar 2004, Rezzani 2004, 2005a, 
2006, Kurus et al. 2008, Bohmer et al. 2011). 
There are two possible mechanisms of CsA-
induced hepatotoxicity: (1) due to an excess of 
free radical production during CsA metabolism in 
the liver; or (2) CsA may impair the antioxidant 
defense (Durak et al. 2004). Rezzani et al. (2005a) 
suggested that the oxidative stress induced by CsA 
is associated with the imbalance of free oxygen 
radical production and the antioxidant defense 
system. The increase of CsA-associated oxidative 
TABLE I
Hepatic parameters of Wistar rats treated with water (control), CsA, 
H. tomentosa infusion or CsA+H. tomentosa infusion for 21 or 56 days.
Parameters
Groups
21 Days 56 Days
CG CsA Ht CsA+Ht CG CsA Ht CsA+Ht
Volumetric Proportions (%)
Hepatocytes 
(% nuclei; 
% cytoplasm)
89.15 ± 
2.39a (11.39 
± 1.28a; 
88.61 ± 
1.28a)
86.17 
± 2.61b 
(12.22 
± 0.69a; 
87.78 ± 
0.69a)
88.48 ± 
1.08ab 
(15.19 
± 1.69b; 
84.81 ± 
1.69b)
90.46 
± 1.50a 
(12.24 ± 
2.37ab; 
87.76 ± 
2.37ab)
90.09 ± 
2.04 (11.85 
± 1.67; 
88.15 ± 
1.67)
90.26 ± 
2.83 (12.72 
± 1.89; 
87.28 ± 
1.89)
89.01 ± 
4.64 (11.88 
± 1.50; 
88.12 ± 
1.50)
88.71 ± 
0.85 (12.12 
± 2.04; 
87.88 ± 
2.04)
Sinusoids 9.43 ± 2.38ab
12.17 ± 
2.87a
9.14 ± 
1.06ab
7.01 ± 
1.26b 8.06 ± 1.56 7.37 ± 3.14 8.71 ± 4.49 8.85 ± 1.09
Kupffer cells 1.41 ± 0.26a 1.65 ± 0.44a 2.38 ± 0.37b 2.52 ± 0.33b 1.85 ± 0.51 2.37 ± 0.45 2.28 ± 0.39 2.45 ± 0.33
Volume (μm3)
Hepatocyte 2501.46 ± 145.0a
2267.7 ± 
313.1ab
1760.0 ± 
242.5c
1887.9 ± 
281.0bc
2265.9 ± 
429.7
2111.2 ± 
205.3
2322.5 ± 
468.4
2525.1 ± 
419.7
HC 2217.9 ± 161.0a
1991.9 ± 
286.5ab
1491.8 ± 
198.1c
1661.73 ± 
286.6bc
2002.7 ± 
416.3
1844.96 ± 
210.8
2050.3 ± 
439.4
2225.0 ± 
418.7
HN 283.55 ± 16.67a
275.80 ± 
29.40a
268.12 ± 
56.89ab
226.19 ± 
21.23b
263.18 ± 
20.25a
266.30 ± 
26.53a
272.22 ± 
38.02ab
300.05 ± 
25.85b
Number of HN per 
area - µm2 (x10-3)
1.00 ± 
0.09a
1.01 ± 
0.13a
1.23 ± 
0.13b
1.07 ± 
0.16ab
0.94 ± 
0.10a
1.03 ± 
0.2ab
1.00 ± 
0.14ab
1.11 ± 
0.01b
Control group (CG), Cyclosporin A treated group (CsA), Heteropterys tomentosa treated group (Ht) and group with simultaneous 
treatment of CsA and H. tomentosa (CsA+Ht). HC: Hepatocyte cytoplasm; HN: Hepatocyte nucleus. The values are mean ± SD. 
In each row, values with different superscripts are significantly different (p<0.05) by Kruskal Wallis Multiple Comparison test.
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TABLE II
Plasma biochemical parameters of Wistar rats treated with water (control), CsA, 
H. tomentosa infusion or CsA+H. tomentosa infusion for 21 or 56 days. 
Parameters
Groups
21 Days 56 Days
CG CsA Ht CsA+Ht CG CsA Ht CsA+Ht 
Glucose (mg/dL) 272.13 ± 43.46a
276.96 ± 
38.77a
301.26 ± 
44.94ab
367.78 ± 
67.54b
305.22 ± 
45.02
317.39 ± 
75.93
300.39 ± 
75.67
293.09 ± 
35.36
Total Cholesterol (mg/dL) 93.29 ± 5.45a
105.42 ± 
7.82b
91.87 ± 
6.35a
103.87 ± 
4.08b
104.26 ± 
5.21a
108.13 ± 
14.58ab
101.03 ± 
7.12a
114.45 ± 
0.07b
Triglycerides (mg /dL) 109.31 ± 7.91ab
105.37 ± 
9.29ab
89.13 ± 
25.38a
124.86 ± 
22.70b
124.77 ± 
19.07
142.02 ± 
22.17
123.07 ± 
27.89
148.53 ± 
30.34
Alkaline Phosphatase 
(U/L) 
109.27 ± 
32.12ab
129.43 ± 
15.40a
72.19 ± 
49.68b
124.67 ± 
101.20ab
86.72 ± 
19.17
81.03 ± 
23.94
76.45 ± 
19.63
97.9 ± 
43.92
Total Proteins (g/dL) 6.3 ± 0.2
6.55 ± 
0.44
6.45 ± 
0.38
6.35 ± 
0.25
7.44 ± 
0.46
6.92 ± 
0.48 7.4 ± 0.58
7.15 ± 
0.17
GOT (U/L) 81.21 ± 20.76ab
114.21 ± 
27.43a
71.36 ± 
8.59b
81.19 ± 
18.60b
86.57 ± 
14.74
91.79 ± 
38.12
81.64 ± 
12.67
82.43 ± 
21.94
GPT (U/L) 41.73 ± 6.26
43.22 ± 
11.32
47.14 ± 
12.75
46.09 ± 
7.74
39.09 ± 
3.50a
57.82 ± 
14.29bc
44.23 ± 
5.84ab
61.04 ± 
5.87c
Creatinine (mg/dL) 0.65 ± 0.11a
0.66 ± 
0.06a
0.78 ± 
0.09ab
0.79 ± 
0.09b
0.75 ± 
0.07
0.80 ± 
0.20
0.73 ± 
0.10
0.75 ± 
0.10
Control group (CG), Cyclosporin A treated group (CsA), Heteropterys tomentosa infusion treated group (Ht) and group with 
simultaneous treatment of CsA and H. tomentosa (CsA+Ht). GOT: Glutamic Oxalacetic Transaminase; GPT: Glutamic Pyruvate 
Transaminase. The values are mean ± SD. In each row, values with different superscripts are significantly different (p<0.05) by 
Kruskal Wallis Multiple Comparison test.
stress is positively correlated with biochemical 
parameter alterations, which are characteristic of 
hepatotoxicity (Hagar 2004).
According to Bohmer et al. (2011), CsA-
associated histopathological changes on the liver 
comprise sinusoidal dilatation, hepatocyte cyto-
plasmic vacuolization, cell infiltration, parenchymal 
mitosis and moderate hepatocellular necrosis. 
Rezzani et al. (2005a) observed evident liver 
morphological alterations caused by CsA (15mg/
kg/day) subcutaneously injected in Wistar rats, for 
30 days. These authors observed widespread cell 
swelling and congestion of sinusoids. Hagar (2004) 
observed, in the rabbits’ liver, severe hydropic 
degeneration in parenchymal cells after treatment 
with CsA (25mg/kg/day, orally during 10 days). 
However, Bohmer et al. (2011), working with CsA 
treated animals (5 and 15mg/kg daily) by gavage 
for 8 weeks, did not observe clear histopathological 
and clinicopathological alterations of the liver, 
which supports our findings. The absence of 
hepatic histopathological impairment observed in 
this study can be related to the dose and route of 
drug administration. Despite the absence of clear 
morphological alteration, the treatment with CsA 
for 21 days reduced the volumetric proportion 
of hepatocytes and increased (not statistically 
significant) the volumetric proportion of sinusoids. 
Bohmer et al. (2011) listed sinusoids dilatation as 
one of the histopathological changes associated 
with CsA administration. However, the authors did 
not explain how CsA induced this change.
CsA-associated fibrosis is largely reported in 
the kidney (Bakker et al. 2003, Ling et al. 2003, 
Li et al. 2004). Hagar (2004) working with CsA 
(25mg/kg daily), administered daily to rabbits, 
observed mild connective tissue proliferation in 
the liver periportal region. However, in the present 
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study, CsA did not cause fibrosis even after 56 days 
of treatment, which was probably due to the lower 
CsA-dose used in our experiment.
The histopathological alterations were 
consistent with the biochemical findings. CsA 
administered for 21 days caused increase of total 
cholesterol and GOT levels. On the other hand, the 
treatment with CsA for 56 days caused an increase 
of GPT levels. Bohmer et al. (2011) did not observe 
alterations of GOT and GPT levels after treatment 
of rats with 15mg/kg/day of CsA by gavage for 
30 days. According to the authors, CsA caused 
immunosuppression without hepatotoxicity. The 
treatment with CsA is known to cause hyperglycemia 
(Neto et al. 1999, Freitas et al. 2012a) however, in 
our study this response was not observed even after 
treatment for 56 days. The simultaneous treatment 
with H. tomentosa and CsA caused an increase 
of glucose and creatinine level after 21 days of 
treatment; these effects were not observed after 
a long term treatment or when the animals were 
treated with only CsA or H. tomentosa.
The increased volumetric proportion of hepa-
tocyte nuclei associated with the infusion treatment 
can be explained by the higher number of hepatocyte 
nuclei (hyperplasia) since an increase of nucleus 
area or volume (hypertrophy) was not observed. The 
increase of hepatocyte nucleus number and Kupffer 
cells proportion could indicate toxicity induced by H. 
tomentosa after the treatment for 21 days. The effect 
of the infusion administration can be associated with 
the acute treatment since after 56 days of treatment 
no alterations caused by the plant could be observed. 
The proliferation of hepatocytes could be related to 
liver recovery after injury (Tan et al. 2014).
The use of antioxidant substances against CsA-
induced hepatotoxicity is reported in literature. The 
efficiency against CsA-induced hepatotoxicity of 
taurine (Hagar et al. 2006), oral L-arginine (Kurus 
et al. 2008), melatonin (Rezzani et al. 2005a) and 
vitamins C and E (Durak et al. 2004) has been 
confirmed. According to Ng et al. (2000) flavonoid 
compounds exhibit antioxidant and free radical 
scavenging properties. Flavonoids are also considered 
as a protective substance against harmful external 
influences (Hassig et al. 1999). Galvao et al. (2002) 
listed flavonoid glycosides among the substances 
present on H. tomentosa root extract. However, 
according to Galvao et al. (2002) it is not possible to 
affirm if the effects of H. tomentosa could be attributed 
to one or more chemical constituents.
In the present study the treatment with H. 
tomentosa together with CsA for 21 days did not 
alter sinusoids and hepatocyte proportions, as found 
for the treatment with CsA (21 days). In addition, 
the alteration observed in GOT levels after the 
treatment with CsA (21 days) was not present for 
animals treated simultaneously with the drug and 
the infusion. However, the simultaneous treatment 
(for 21 days) caused alterations of glucose and 
creatinine levels. The alteration of GPT levels 
caused by CsA (56 days) also occurred in the 
CsA+Ht group. The absence of hepatotoxicity 
after 56 days of CsA administration did not allow 
the evaluation of H. tomentosa protection. The 
simultaneous treatment administered for 56 days 
did not induce hepatotoxicity.
Freitas et al. (2013), working with Wistar 
rats treated with CsA, H. tomentosa and both 
substances, observed an increase of GOT, bilirubin 
(total and indirect), triglycerides, cholesterol and 
glucose levels caused by CsA. They also observed 
that animals treated simultaneously with CsA and 
infusion showed normalization of GOT, triglycerides 
and glucose levels. The above authors did not 
observe any alterations caused by H. tomentosa on 
biochemical parameters of hepatotoxicity. Freitas et 
al. (2013) worked with 90 days-old Wistar rats and 
the animals were treated for 56 days with the same 
dose of CsA and H. tomentosa used in the present 
study. The differences between the present results 
and the findings of Freitas et al. (2013) could be due 
to the time of drug administration (in the case of the 
animals treated for 21 days), the different source of 
An Acad Bras Cienc (2015) 87 (1)
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H. tomentosa roots, animals’ initial age (we started 
the experiment with 56 days-old animals) or the 
animals’ individual sensibility to the treatment.
CONCLUSIONS
The results suggested that the treatment with CsA 
for 21 days caused hepatotoxicity which was 
reduced over a longer administration period (56 
days). Possibly the hepatic defense system against 
higher oxidative stress was able to recover during 
this period with an increase of the enzymes involved 
in free radical elimination. H. tomentosa caused 
alterations of some of the parameters analyzed, 
mainly after 21 days of treatment. The association 
with the plant administration and hepatotoxicity 
has to be better studied. The simultaneous treatment 
with CsA and H. tomentosa did not accentuate nor 
attenuate the CsA-related side-effects studied.
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RESUMO
A Ciclosporina A (CsA) é uma droga imunossupressora 
amplamente utilizada que está associada a diversos efeitos 
colaterais, dentre eles hepatotoxicidade. Heteropterys 
tomentosa é uma planta brasileira eficiente na redução 
dos danos causados pela CsA nos testículos e próstata de 
ratos. O objetivo deste estudo foi avaliar o efeito da CsA e 
H. tomentosa (administrados isolada ou simultaneamente) 
no fígado de ratos Wistar. Os animais foram tratados 
diariamente com água (controle), CsA (15mg/kg/dia), 
infusão de H. tomentosa ou CsA+H. tomentosa, por 21 
ou 56 dias. Os tratamentos não alteraram a morfologia 
do fígado nem causaram fibrose. A administração de 
H. tomentosa por 21 dias aumentou o número de núcleos 
de hepatócitos e proporção volumétrica de células de 
Kupffer. Após 56 dias de tratamento, a administração de 
H. tomentosa não alterou os parâmetros analisados. 
As dosagens bioquímicas plasmáticas e a estereologia 
do fígado revelaram danos causados pelo tratamento 
com CsA por 21 dias; estes resultados não foram 
observados após 56 dias de tratamento. O tratamento 
simultâneo com CsA e H. tomentosa por 21 e 56 dias 
não atenuou ou acentuou os efeitos hepáticos da CsA. 
O presente estudo revelou que o tratamento com a 
CsA por 21 dias causou mais alterações ao fígado que o 
tratamento durante 56 dias; isso pode estar relacionado 
a recuperação hepática após o tratamento a longo prazo.
Palavras-chave: hepatotoxicidade, Heteropterys aphro­
disiaca, planta medicinal, fitoterapia.
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